The Future of Glaucoma Treatment Ripasudil

Nada Elsayed Abdel Fattah Amer;

Abstract


SUMMARY
G
laucoma refers to a group of related eye disorders that have in common an optic neuropathy associated with visual function loss. It is one of the leading causes of irreversible blindness worldwide. Glaucoma can damage vision gradually so it may not be noticed until the disease is at an advanced stage.
Ripasudil (K-115) is a newly approved glaucoma treatment that is able to achieve potent IOP-lowering effects via its action as a selective Rho kinase inhibitor. K-115 is the first Rho-kinase inhibitor ophthalmic solution developed for the treatment of glaucoma and ocular hypertension in Japan 2014.
Rho-kinase (Rho-associated coiled-coil containing protein kinase; ROCK), a member of the serine-threonine protein kinases, is an effector protein of low molecular weight protein, Rho. Rho kinase binds with Rho to form a Rho/Rho-kinase complex, and regulates various physiological functions, such as smooth muscle contraction, chemotaxis, neural growth, and gene expression.
ROCK has two isoforms, ROCK-1 and ROCK-2, which are extensively distributed throughout in various tissues. Both ROCK-1 and ROCK-2 are also widely-expressed in ocular tissues including the ciliary muscles, trabecular meshwork, iris, and retina, among others. ROCK inhibitors have demonstrated efficacy in reducing intraocular pressure (IOP).


Other data

Title The Future of Glaucoma Treatment Ripasudil
Other Titles ريباسوديل العلاج الجديد للجلوكوما
Authors Nada Elsayed Abdel Fattah Amer
Issue Date 2017

Attached Files

File SizeFormat
J3138.pdf226.36 kBAdobe PDFView/Open
Recommend this item

Similar Items from Core Recommender Database

Google ScholarTM

Check

views 10 in Shams Scholar
downloads 4 in Shams Scholar


Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.